CymoGen Dx

New Windsor, United States Founded: 2010 • Age: 16 yrs Acquired By Biocare Medical
Genomic-based reagents and FISH probes are developed for cancer diagnostics.
Request Access

About CymoGen Dx

CymoGen Dx is a company based in New Windsor (United States) founded in 2010 was acquired by Biocare Medical in October 2014.. CymoGen Dx has raised $350.16 thousand across 1 funding round from investors including Biocare Medical. CymoGen Dx offers products and services including FISH Probes, Primary Antibodies, and Detection Systems. CymoGen Dx operates in a competitive market with competitors including Guardant Health, Abcam, Foundation Medicine, ArcherDX and Natera, among others.

  • Headquarter New Windsor, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Biocare Medical, Llc
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $350.16 K (USD)

    in 1 rounds

  • Latest Funding Round
    $350.16 K (USD), Seed

    Jul 06, 2010

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Biocare Medical

    (Oct 03, 2014)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of CymoGen Dx

CymoGen Dx offers a comprehensive portfolio of products and services, including FISH Probes, Primary Antibodies, and Detection Systems. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Tools for detecting genomic changes in cancer tissues

Reagents for tissue staining and analysis

Kits for fluorescence and hybridization processes

Funding Insights of CymoGen Dx

CymoGen Dx has successfully raised a total of $350.16K through 1 strategic funding round. The most recent funding activity was a Seed round of $350.16 thousand completed in July 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $350,161
  • First Round

    (06 Jul 2010)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2010 Amount Seed - CymoGen Dx Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in CymoGen Dx

CymoGen Dx has secured backing from 1 investor. Prominent investors backing the company include Biocare Medical. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Primary antibodies and instruments for immunohistochemistry are manufactured.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by CymoGen Dx

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - CymoGen Dx

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cymogen Dx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of CymoGen Dx

CymoGen Dx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Abcam, Foundation Medicine, ArcherDX and Natera, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Biological reagents and antibodies are developed for life science research.
domain founded_year HQ Location
Genomics-based diagnostic tests for cancer are provided.
domain founded_year HQ Location
Molecular cancer diagnostic products are developed using patented AMP technology.
domain founded_year HQ Location
Developer of cell-free DNA testing for oncology, women’s health, and organ health
domain founded_year HQ Location
Genomic technologies and drug discovery platforms are provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Cymogen Dx

Frequently Asked Questions about CymoGen Dx

When was CymoGen Dx founded?

CymoGen Dx was founded in 2010.

Where is CymoGen Dx located?

CymoGen Dx is headquartered in New Windsor, United States. It is registered at New Windsor, New York, United States.

Is CymoGen Dx a funded company?

CymoGen Dx is a funded company, having raised a total of $350.16K across 1 funding round to date. The company's 1st funding round was a Seed of $350.16K, raised on Jul 06, 2010.

What does CymoGen Dx do?

CymoGen Dx was founded in 2010 in New Windsor, United States, within the biotechnology sector focused on genomics. Next-Gen FISH probes are produced to detect chromosomal aberrations in FFPE tissues, bone marrow, aspirates, and blood samples, aiding research on hematologic and solid tumor cancers. A GMP-compliant fluorescent labeling system is also provided for these applications. Operations center on reagent development for diagnostic and study purposes.

Who are the top competitors of CymoGen Dx?

CymoGen Dx's top competitors include Guardant Health, Abcam and Strand Life Sciences.

What products or services does CymoGen Dx offer?

CymoGen Dx offers FISH Probes, Primary Antibodies, and Detection Systems.

Who are CymoGen Dx's investors?

CymoGen Dx has 1 investor. Key investors include Biocare Medical.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available